Firategrast

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameFirategrast
Drug Alias NameFirategrastum非拉司特菲泰司特T-0047SB-683699
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-4/beta-1 antagonists
TargetsIntegrin alpha-4/beta-1
Therapy Area/IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisCrohn Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[19] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisCrohn Disease

Other Information

ATC CodeN/A
Related LinksKEGG